Gel4Med, Inc.

Gel4Med is a commercial-stage biomaterials company founded from Harvard Innovation Labs, developing novel biosynthetic wound care and surgical reconstruction products using proprietary Smart Materials Platform (SMP™) technology. The company specializes in self-assembling peptide-based matrices engineered to address complex wound management and high-risk surgical closure. Their lead products, G4Derm™ Plus and Suprello™ Wound Matrix, both received FDA 510(k) clearance in October 2023. G4Derm™ Plus is a flowable biomimetic matrix for complex wound management, while Suprello™ is a peptide-based wound matrix for secure closure and healing in high-risk surgical cases. The company's platform approach enables development of advanced biomaterials for wound care and surgical reconstruction applications. Gel4Med has received significant funding from the National Institutes of Health Commercial Readiness Pilot program and U.S. Department of Defense, and is collaborating with the University of Miami on spinal cord injury treatments. The company maintains R&D facilities at UMass Lowell and headquarters in Brighton, Massachusetts. Products are indicated for wound care, surgical reconstruction, and tissue management applications.